Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 6/2020

01-06-2020 | Prostate Cancer | Original Article

Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study

Authors: Harutake Sawazaki, Daiji Araki, Yosuke Kitamura, Kota Yagi

Published in: World Journal of Urology | Issue 6/2020

Login to get access

Abstract

Purpose

In a mouse model, degarelix generated the least metabolic consequences via low follicle-stimulating hormone (FSH) levels compared with orchiectomy and leuprolide after 4 months of androgen deprivation therapy (ADT). Here, we comparatively investigated the influence of ADT with degarelix or leuprolide on the development of metabolic syndrome in patients with prostate cancer (PCa).

Methods

Patients with hormone-naive PCa were recruited. Eligible patients were randomized (1:1) to monthly degarelix or monthly leuprolide for 6 months. Key trial variables were monitored monthly. The primary endpoint was changes in fasting blood sugar (FBS). Secondary endpoints were changes in body weight, abdominal circumference, lipid profiles, and hemoglobin A1c (HbA1c) and FSH levels. Computed tomography was performed to measure subcutaneous and visceral fat areas before and after 6 months of ADT. Data were analyzed using the χ2 test, Student’s t test, and analysis of variance.

Results

From the 100 patients registered, 85 completed the trial (degarelix: 40 patients; leuprolide: 45 patients). Mean increases in FBS did not differ between the two arms. Similarly, there were no differences between the arms in mean increases in body weight, abdominal circumference, lipid profiles, HbA1c, or subcutaneous and visceral fat areas. Follicle-stimulating hormone levels were significantly lower in the degarelix arm than in the leuprolide arm (p < 0.05).

Conclusions

Lipid and glucose metabolism did not differ significantly between the arms, while FSH levels were significantly lower in the degarelix arm.
Literature
1.
Bo JJ, Zhang C, Zhang LH et al (2011) Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks. Asian J Androl 13:833–837CrossRef
2.
Tzortzis V, Samarinas M, Zachos I et al (2017) Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones 16(2):115–123PubMed
3.
Mitsuzuka K, Kyan A, Sato T et al (2016) Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis 19:57–62CrossRef
4.
Bosco C, Crawley D, Adolfsson J et al (2015) Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLOS One 20 10(3):e0117344CrossRef
5.
Hopmans SN, Duivenvoorden WC, Werstuck GH et al (2014) GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 32:1126–1134CrossRef
6.
Liu XM, Chan HC, Ding GL et al (2015) FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca2+/CREB pathway. Aging Cell 14:409–420CrossRef
7.
Østergren PB, Kistorp C, Fode M et al (2019) Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU Int 123:602–611CrossRef
8.
Vargas A, Machado RD, Filho DI et al (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34:1621–1628CrossRef
9.
Sjöström L, Kvist H, Cederblad A et al (1986) Determination of total adipose tissue and body fat in women by computed tomography, 40 K, and tritium. Am J Physiol 250:E736–E745PubMed
10.
Parikh RM, Mohan V (2012) Changing definitions of metabolic syndrome. Indian J Endocrinol Metab 16(1):7–12CrossRef
11.
Nishiyama T, Ishizaki F, Anraku T et al (2005) The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90(2):657–660CrossRef
12.
Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: 12-month, comparative, randomized, open-label, parallel-group phase 3 study in patients with prostate cancer. BJU Int 102:1531–1538CrossRef
13.
Saylor PJ, Smith MR (2010) Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw 8(2):211–223CrossRef
Metadata
Title
Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study
Authors
Harutake Sawazaki
Daiji Araki
Yosuke Kitamura
Kota Yagi
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 6/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02937-x

Other articles of this Issue 6/2020

World Journal of Urology 6/2020 Go to the issue

Letter to the Editor

Extent of lymph node dissection improves overall survival in pT3N0 non-metastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis

Original Article

Holmium laser enucleation of the prostate versus thulium laser enucleation of the prostate for the treatment of large-volume prostates > 80 ml: 18-month follow-up results

Invited Review

Systematic review: bacterial colonisation of conduits and neobladders—when to test, watch, and treat

Original Article

Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis

Original Article

Effect of optical fiber diameter and laser emission mode (cw vs pulse) on tissue damage profile using 1.94 µm Tm:fiber lasers in a porcine kidney model

Original Article

Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate